NS5A is a membrane-associated phosphoprotein involved in
both the formation of the replication complex and in the virus
assembly. The most potent HCV NS5A inhibitor reported to date
Searching for new antiviral therapies | 73
is BMS-790052, currently in phase II clinical trial in combination
with SoC. It was also used in combination with a protease
inhibitor (BMS-650032) for retreatment of previous nonresponders
to SoC with good results, but only in association with
PegIFN/RBV. Exclusion of SoC from the therapeutic regimen
resulted in high rates of viral breakthrough through week 12.
both the formation of the replication complex and in the virus
assembly. The most potent HCV NS5A inhibitor reported to date
Searching for new antiviral therapies | 73
is BMS-790052, currently in phase II clinical trial in combination
with SoC. It was also used in combination with a protease
inhibitor (BMS-650032) for retreatment of previous nonresponders
to SoC with good results, but only in association with
PegIFN/RBV. Exclusion of SoC from the therapeutic regimen
resulted in high rates of viral breakthrough through week 12.
No comments:
Post a Comment